Patents by Inventor Karl Bruce Thor

Karl Bruce Thor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Ca2.2 subunit calcium channel modulators
    Patent number: 7084116
    Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painful lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.
    Type: Grant
    Filed: March 10, 2004
    Date of Patent: August 1, 2006
    Assignee: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard
  • 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof
    Patent number: 6864262
    Abstract: The present invention provides a compound of the formula (I) and the pharmaceutically acceptable salts and solvates thereof, which is useful for treating bladder over-activity or urinary incontinence.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: March 8, 2005
    Assignee: Eli Lilly and Company
    Inventors: John Mehnert Schaus, Dennis Charles Thompson, Karl Bruce Thor
  • Methods of treating lower urinary tract disorders using sodium channell modulators
    Publication number: 20040209960
    Abstract: The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat painful and non-painful lower urinary tract disorders, particularly painful and non-painful overactive bladder with and/or without loss of urine.
    Type: Application
    Filed: January 30, 2004
    Publication date: October 21, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Edward C. Burgard, Karl Bruce Thor, Matthew Oliver Fraser
  • Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators
    Publication number: 20040198822
    Abstract: A method is provided for using &agr;2&dgr; subunit calcium channel modulators or other compounds that interact with the &agr;2&dgr; calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, &agr;2&dgr; subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, &bgr;3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: March 22, 2004
    Publication date: October 7, 2004
    Applicant: Dynogen Pharmacueticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
  • Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using Cav2.2 subunit calcium channel modulators
    Publication number: 20040198775
    Abstract: The invention relates to methods of using Cav2.2 subunit calcium channel modulators to treat painful and non-painfull lower urinary tract disorders and the related genitourinary tract disorders vulvodynia and vulvar vestibulitis in normal and spinal cord injured patients.
    Type: Application
    Filed: March 10, 2004
    Publication date: October 7, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard
  • Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction
    Publication number: 20040192730
    Abstract: A method is provided for using compounds that exhibit combined activities as 5-HT1A active agents and selective serotonin reuptake inhibitors (SSRI's) to treat sexual dysfunction, particularly premature ejaculation, on an as-needed basis shortly before sexual activity.
    Type: Application
    Filed: March 12, 2004
    Publication date: September 30, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventor: Karl Bruce Thor
  • Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators
    Publication number: 20040142034
    Abstract: A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an &agr;2&dgr; subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that interact with the &agr;2&dgr; calcium channel subunit.
    Type: Application
    Filed: December 19, 2003
    Publication date: July 22, 2004
    Applicant: Dynogen Pharmaceuticals, Inc.
    Inventors: Karl Bruce Thor, Edward C. Burgard, Matthew Oliver Fraser
  • 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof
    Publication number: 20040067962
    Abstract: The present invention provides a compound of the formula (I), and the pharmaceutically acceptable salts and solvates thereof, which is useful for treating bladder over-activity or urinary incontinence.
    Type: Application
    Filed: May 21, 2003
    Publication date: April 8, 2004
    Inventors: John Mehnert Schaus, Dennis Charles Thompson, Karl Bruce Thor